Cite
HARVARD Citation
Lee, D. et al. (n.d.). 363OTreatment with pralsetinib (formerly BLU-667), a potent and selective RET inhibitor, provides rapid clearance of ctDNA in patients with RET-altered non-small cell lung cancer (NSCLC) and medullary thyroid cancer (MTC). Annals of oncology. p. . [Online].